Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals and Novavax, has completed construction of its vaccine facility in Dholka, India and is expected to initiate equipment and installation validation very soon so that the facility conforms to global standards for production of vaccines for human use.
Subscribe to our email newsletter
CPLB said that the new facility utilises equipment for fast and efficient production of up to potentially 60 million doses of novel vaccines every year.
The facility plans to produce seasonal and pandemic flu vaccines based on Novavax’s advanced virus-like particle (VLP) technology which enables the rapid development and production of novel vaccines without the use of live virus.
IA Modi, chairman of Cadila Pharmaceuticals, said: “This facility demonstrates our commitment to establishing the highest-quality vaccine production facility for our nation. It utilises design and equipment that will be competitive with the world’s leading vaccine companies.”
Rahul Singhvi, president and CEO of Novavax, said: “We congratulate our colleagues at CPL Biologicals on reaching this important milestone in the development of a vaccine production facility.
“This achievement reflects our strategy to partner with pharmaceutical companies around the world to develop, in-country vaccine-production capacity and use our novel vaccine technology to solve critical public health problems.
“This world class vaccine production plant in India will be able to supply India and other countries with novel vaccines against influenza and other infectious diseases by using an efficient, reliable and flexible vaccine production process.”